PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
20 déc. 2024 16h55 HE
|
PharmAla Biotech
PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement
PharmAla Announces Private Placement
13 déc. 2024 09h25 HE
|
PharmAla Biotech
PharmAla announces private placement financing
Psychedelic Science 2025 Conference Announces Workshops, Holiday Sale, and Scholarship Deadline
05 déc. 2024 15h44 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
14 nov. 2024 09h20 HE
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
07 nov. 2024 09h20 HE
|
PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
21 oct. 2024 09h25 HE
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
08 oct. 2024 08h55 HE
|
PharmAla Biotech
PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
02 oct. 2024 09h20 HE
|
PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
MAPS Awards Grant for Pilot MDMA-assisted Massed Exposure Therapy Trial
27 août 2024 07h00 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...